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a b s t r a c t
Curcumin has been shown to have many potentially health beneﬁcial properties in vitro and in animal
models with clinical studies on the toxicity of curcumin reporting no major side effects. However,
curcumin may chelate dietary trace elements and could thus potentially exert adverse effects. Here, we
investigated the effects of a 6 month dietary supplementation with 0.2% curcumin on iron, zinc, and
copper status in C57BL/6J mice. Compared to non-supplemented control mice, we observed a signiﬁcant
reduction in iron, but not zinc and copper stores, in the liver and the spleen, as well as strongly
suppressed liver hepcidin and ferritin expression in the curcumin-supplemented mice. The expression of
the iron-importing transport proteins divalent metal transporter 1 and transferrin receptor 1 was
induced, while hepatic and splenic inﬂammatory markers were not affected in the curcumin-fed mice.
The mRNA expression of other putative target genes of curcumin, including the nuclear factor (erythroid-
derived 2)-like 2 and haem oxygenase 1 did not differ between the groups. Most of the published animal
trials with curcumin-feeding have not reported adverse effects on iron status or the spleen. However, it is
possible that long-term curcumin supplementation and a Western-type diet may aggravate iron
deﬁciency. Therefore, our ﬁndings show that further studies are needed to evaluate the effect of
curcumin supplementation on iron status.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
The phytochemical curcumin (diferuloylmethane) is found in the
rhizome of Curcuma longa (family Zingiberaceae) and is responsible for
the intense yellow pigmentation of turmeric and the curry blends
prepared therewith [1]. Curcumin is used in traditional medicine to
treat disorders such as anorexia, biliary complaints, cough, hepatic
diseases, and sinusitis [2]. Many positive properties have been
attributed to curcumin such as antioxidative, anti-proliferative, anti-
inﬂammatory, and anti-amyloidogenic effects in vitro and in animal
models [1,3]. Therefore, interest in the use of curcumin as a potentially
health-beneﬁcial agent has been increasing.
Curcumin preparations have been “generally recognised as safe”
(GRAS) by the FDA (http://www.accessdata.fda.gov/scripts/fcn/gras_
notices/GRN000460.pdf) and in patients with pre-malignant lesions,
high-dose supplementation with 4–8 g/d for up to 3 months was
without adverse effects [4]. In a recent cell culture experiment using
endothelial cells, however, concentrations as low as 100 nmol/L
induced mitotic catastrophe [5]. Another property of the phytochem-
ical that may lead to potential adverse effects is its iron chelating
activity [6–8], which is particularly effective for ferric ions [7].
Although it has been shown that meals spiced with turmeric (0.5 g/
meal) did not affect iron absorption in women [9], long-term
supplementation with higher concentrations of curcumin (2% by
weight) induced systemic iron depletion and further aggravated iron
deﬁciency symptoms in young mice when fed with diets containing
low iron concentrations (5 mg/kg diet) [10]. In addition to chelating
iron and thereby limiting iron release, curcumin has an anti-coagulant
activity [11,12] and may increase bleeding time [13,14]. As internal
bleeding or haemorrhaging can affect iron status, anti-coagulant
activities of curcumin might also contribute to iron deﬁciency.
Native curcumin has very low bioavailability [15] and, hence,
limited therapeutic efﬁcacy. In many intervention studies, the
phytochemical is consequently administered at gram doses
[4,16,17]. If curcumin indeed impairs iron status, this high-dose
supplementation may harbour potential risks that need to be
studied in more detail. In order to explore whether long-term oral
supplementation with curcumin affects iron stores, we fed female,
12 month old C57BL/6J mice with 0.2% dietary curcumin for
6 months and determined iron status and the expression of genes
involved in iron homoeostasis at mRNA and protein levels.
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Materials and methods
Mice and diet
The animal study was performed according to German animal
welfare laws and regulations, and with permission from the
responsible authorities. Thirty female, 12 month old C57BL/6J mice
were purchased from Charles River Germany (Sulzfeld, Germany).
The mice were housed in groups of 5 in macrolon cages under
controlled environmental conditions of 55% relative humidity, 22-
24 1C, and a 12-hour light-dark cycle. The mice were maintained
on a semi-synthetic Western-type diet (C1000 mod., Altromin,
Lage, Germany) containing 20% milk fat, 1.25% cholesterol, and 10%
sugar. The concentrations of iron, zinc, and copper in the diet were
178, 28, and 5 mg/kg respectively. The mice were given free access
to tap water. For the ﬁrst 4 weeks, all mice were fed a Western-
type diet without curcumin ad libitum to acclimatize them to the
new diet. Subsequently, the mice were randomly assigned to two
body weight-matched diet groups, namely the control and the
curcumin-supplemented groups. Curcumin supplementation was
at 0.2% (by weight) in the diet for 28 weeks, during which
curcumin-supplemented mice were given ad libitum access to
chow. Since food intake slightly decreased upon curcumin supple-
mentation (most likely due to its bitter taste), the control mice
were pair fed. We lost four mice in the control group and one
mouse in the curcumin group during the supplementation period
so that 11 and 14 mice were available for analyses in the control
and curcumin groups, respectively. At the end of the trial, the mice
were anaesthetised with carbon dioxide and killed by cervical
dislocation. Liver and spleen were weighed, snap-frozen in liquid
nitrogen, and stored at 80 1C until analysis. One part of the
tissues was stored in RNAlater™ (Qiagen, Hilden, Germany) at
20 1C for RNA isolation and qRT-PCR analysis.
Measurement of trace elements in the liver and the spleen
Iron, zinc, and copper were determined using ﬂame atomic
absorption spectrometry (AAS, Thermo S2 AA System, Thermo
Electron Corporation, Germany) as previously described [18].
Weighed liver and spleen samples were ashed and dissolved in
2.1 mol/L HNO3 prior to AAS analysis. Standard curves were
determined with at least 4 different concentrations. Absorption
wavelengths used for iron, zinc, and copper were 248.4 nm,
214 nm, and 324.8 nm respectively.
RNA isolation and quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA of liver and spleen was isolated using the NucleoSpins
kit according to the manufacturer's protocol (Macherey & Nagel,
Düren, Germany). RNA concentration was determined by measuring
the absorbance at 260 nm on a spectrophotometer (Beckmann
Instruments, Munich, Germany) and RNA purity was determined by
calculating 260/280 nm and 260/230 nm ratios. RNA aliquots were
then stored at 80 1C until qRT-PCR analysis. The qRT-PCR primers
were designed using Primer3 Input software (version 0.4.0; Table 1)
and purchased from Euroﬁns MWG (Ebersberg, Germany). One-step
quantitative reverse transcriptase PCR was carried out with the
SensiMix™ SYBR No-ROX one step kit (Bioline, Luckenwalde, Ger-
many) and with SybrGreen detection using the Rotorgene 6000 cycler
(Corbett Life Science, Sydney, Australia). An external standard curve
was applied. The mRNA concentrations of the target genes were
normalised for the mRNA concentrations of the respective house-
keeping genes. The mean value of the relative mRNA expression in the
control group was set to an arbitrary unit of 1 and that in the
curcumin group is expressed as a multiple of the control value.
Western blotting
Cytosolic fractions of liver tissue lysed in RIPA buffer were used to
investigate ferritin light chain protein levels. Protein concentrations
were determined with the BCA assay (BioRad, Munich, Germany) and
60 μg protein of each sample was mixed with loading buffer,
denatured at 95 1C for 5 min, and separated on 4–20% MINI PRO-
TEANs TGX-Stain-Free™ gels (BioRad, Munich, Germany). Subse-
quently, proteins were activated by UV-exposure for 5 min and then
transferred onto a PVDF membrane using the Trans Blots Turbo™
System (BioRad, Munich, Germany). The membrane was blocked with
3% skim milk dissolved in TBSþ0.05% Tween-20 (TBS/T) for at least
2 h and probedwith a ferritin light chain (ab69090 Abcam, Cambridge,
UK; 1:1000) antibody at 4 1C overnight. After incubation with a
horseradish-peroxidase-conjugated secondary anti-rabbit antibody,
the bands were visualised by using ECL reagent (Thermo Scientiﬁc,
Schwerte, Germany) in a ChemiDoc XRS system (BioRad, Munich,
Germany). Normalisation was carried out with reference to the total
lane protein as determined using the stain-free technology by Bio-Rad.
Statistical analysis
Statistical analysis was performed using SPSS version 19.0
(SPSS GmbH Software, Munich, Germany). Normal distribution of
data was tested by Kolmogorov–Smirnov and Shapiro–Wilk tests
and normally distributed data were analysed using Student's
t-test. When data were not normally distributed, a Mann–Whitney
U test was performed. Results are presented as meansþSEM and
P-valueso0.05 were considered statistically signiﬁcant.
Results
Long-term feeding with 0.2% curcumin does not affect body weight
development but induces splenomegaly in C57BL/6J mice
The weight of the mice in the control group and those receiving
oral supplementation of 0.2% curcumin over 28 weeks did not differ
signiﬁcantly (Fig. 1). The 12 month old mice had an average body
weight of 28.270.4 g at the beginning of the supplementation
period and had an average body weight of 37.171.0 g at the end of
the study. Despite similar weight development curves between
control and curcumin-supplemented mice, we observed an enlar-
gement of the spleen (Po0.05) in the curcumin group (Fig. 2). On
average, spleen mass of the curcumin-supplemented mice was 40%
higher (Fig. 2a) than that of the control mice. In 4 out of 14
Table 1
Nucleotide sequences (5'-3') of murine primers used for the quantitative real-
time PCR.
Gene Gene
ID
Primer sequence forward Primer sequence reverse
β-actin 11461 GACAGGATGCAGAAGAGATTACT TGATCCACATCTGCTGGAAGGT
γGCS 14629 GTGGAGGCCAATATGAGGAA GGGTGCTTGTTTATGGCTTC
DMT1 18174 GAGCAGTGGCTGGATTTAAG CGGTGACATACTTCAGCAAG
Ferritin L 14325 CTTCCAGGATGTGCAGAAG ATCCAAGAGGGCCTGATT
FPN 53945 CAAACTACCTGACCTCAGCA TCCACCAGAAACACAGACAC
GAPDH 14433 CCGCATCTTCTTGTGCAGT GGCAACAATCTCCACTTTGC
HEPC 84506 GCACCACCTATCTCCATCA GGGGAAGTTGGTGTCTCTC
HO1 15368 GAGCCTGAATCGAGCAGAAC AGCCTTCTCTGGACACCTGA
IL1β 16176 CAGGCAGGCAGTATCACTCA AGCTCATATGGGTCCGACAG
IL6 16193 AGTTGCCTTCTTGGGACTGA CAGAATTGCCATTGCACAAC
NQO1 18104 TTCTCTGGCCGATTCAGAGT TCCAGACGTTTCTTCCATCC
NRF2 18024 GCAACTCCAGAAGGAACAGG GCAATGTCTCTGCCAAAAGC
TfR1 22042 AAGCCAGATCAGCATTCTCT CGGCATTTTCTTCTTCATCT
TNFα 21926 TCGTAGCAAACCACCAAGTG AGATAGCAAATCGGCTGACG
D. Chin et al. / Redox Biology 2 (2014) 563–569564
curcumin-fed mice, however, we noted splenomegaly with spleen
mass of more than double the average of the control group. The
mass of the liver (Fig. 2b) and other organs such as lung, heart, and
kidney (data not shown) was also measured, but did not differ
signiﬁcantly between the groups. The livers of our mice showed
signs of hepatic steatosis known to be caused by high-fat diet [19].
Curcumin supplementation reduces iron stores in the liver and spleen
but does not affect zinc and copper content in either tissue
Iron stores in the liver and spleen were signiﬁcantly (Po0.001
and Po0.05, respectively) reduced by ca. 50% in the curcumin-fed
compared to the control mice (Fig. 3a and b). Tissue concentra-
tions of zinc and copper were determined in the liver and spleen
because these elements are known to interact with iron during
absorption and trafﬁcking [20,21]. Furthermore, curcumin has
been reported as chelating zinc and copper [22,23]. In the liver,
neither zinc nor copper stores were affected by curcumin supple-
mentation (Fig. 3c and e). Zinc concentration in the spleen did not
differ between control and curcumin-supplemented mice (Fig. 3d)
and copper concentrations in the spleen were below the limit of
detection (2 mg/kg) in both groups.
Curcumin supplementation reduced mRNA expression and protein
expression of the iron storage protein ferritin in the liver
Relative mRNA of ferritin light (L) chain 1, one of the two
subunits of the intracellular iron storage protein ferritin, was
signiﬁcantly down-regulated (Po0.05) by dietary curcumin
(Fig. 4a). The expression of ferritin heavy (H) chain 1 mRNA did
not differ between the groups (data not shown). Furthermore, the
protein concentrations of ferritin L were signiﬁcantly reduced in
the liver of curcumin-fed mice (Po0.001; Fig. 4b).
Curcumin supplementation reduced mRNA expression of iron
regulatory protein hepcidin and altered mRNA expression of iron
transport proteins in the liver
In the liver of curcumin-supplemented mice, we observed a
65% reduction in hepcidin mRNA levels in comparison to the
controls (Po0.01; Fig. 5a), reﬂecting the depleted endogenous
iron stores in the curcumin-supplemented mice. Ferroportin (FPN),
a known receptor of hepcidin [24], was not signiﬁcantly regulated
at the transcriptional level (Fig. 5b). The mRNA of two iron
transporters: divalent metal transporter (DMT) 1 and transferrin
receptor (TfR) 1 (Fig. 5c and d) was also signiﬁcantly up-regulated
in response to curcumin supplementation.
Inﬂammatory markers in the liver and the spleen were not regulated
by curcumin supplementation in mice
The mRNA expression of pro-inﬂammatory markers, the
tumour necrosis factor α (TNFα), interleukin (IL) 1β, and IL6 in
the liver and the spleen did not differ between the groups
(Table 2), indicating that the observed splenomegaly may not be
related to increased systemic inﬂammation. In contrast to reports
found in the literature [25–27] and despite the long-term supple-
mentation, curcumin did not exert anti-inﬂammatory effects in
our mouse study.
Curcumin supplementation did not induce nuclear factor (erythroid-
derived 2)-like 2 (NRF2) and NRF2-inducible enzymes in the liver
Curcumin has often been reported in the literature as inducing
NRF2 and particularly NRF2-dependent enzyme haem oxygenase
(HO) 1 [28–30]. Therefore, we measured NRF2 and HO1, as well as
two other NRF2-dependent enzymes, NAD(P)H quinone oxidoreduc-
tase (NQO1) and γ-glutamyl cysteine synthetase (γ-GCS) heavy chain
in the liver (Table 2). The mRNA expressions of all four genes were not
signiﬁcantly different between the curcumin-supplemented and con-
trol groups.
Discussion
Our study aimed at investigating the effects of a 6 month 0.2%
dietary curcumin supplementation on iron status and iron trans-
port proteins in the liver and the spleen of adult mice. As the iron
concentrations in the liver and the spleen of our curcumin-fed
mice were signiﬁcantly reduced compared to the controls, the
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Fig. 1. Weight development of control and curcumin-supplemented C57BL/6J mice over
the 28 week supplementation period did not show signiﬁcant differences between
control and curcumin-supplemented mice. Values are expressed as meansþSEM.
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Fig. 2. The mass of (a) spleen and (b) liver of control and curcumin-supplemented C57BL/6J mice after the 28 week supplementation period. Curcumin-supplemented mice
had signiﬁcantly higher spleen mass compared to control mice. No signiﬁcant differences could be observed for liver mass. Values are expressed as meansþSEM. nPo0.05.
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Fig. 3. (a) The iron concentration in the liver, (b) iron concentration in the spleen, (c) zinc concentration in the liver, (d) zinc concentration in the spleen, and (e) copper
concentration in the liver of control and curcumin-supplemented C57BL/6J mice. The concentrations of trace elements are expressed in mg per kg tissue (wet mass). Iron
concentration was signiﬁcantly lower in curcumin-supplemented mice in both the liver and the spleen. The concentrations of zinc and copper were not signiﬁcantly
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Control Curcumin
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Fe
rr
iti
n 
L 
m
R
N
A 
co
nc
en
tr
at
io
n
*
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Control Curcumin
Fe
rr
iti
n 
L 
[r
el
. p
ro
te
in
 le
ve
ls
]
***
Con  Curc   Con  Curc   Con   Curc
20 kDa
Fig. 4. (a) Ferritin light (L) chain 1 mRNA levels in the liver of control and curcumin-supplemented C57BL/6J mice. Relative mRNA concentration was assessed using qRT-PCR
and related to the average of two housekeeping genes (β-actin and GAPDH). Mean ferritin L concentration in the control group was set to be 1. The mRNA expression of
ferritin L was signiﬁcantly lower in curcumin-supplemented mice. Values are expressed as meansþSEM. nPo0.05. (b) Relative protein levels of ferritin L in the liver of
control and curcumin-supplemented C57BL/6J mice as determined by Western blotting of the cytosolic fraction. Relative intensities of bands were quantiﬁed by
densitometry and total lane protein was used as a loading control. Mean band intensity in the control group was set to be 1. Relative protein levels of ferritin L were
signiﬁcantly lower in curcumin-supplemented mice. Con, control group; Curc, curcumin group. Values are expressed as meansþSEM. nnnPo0.001.
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present study shows that long-term oral supplementation with
curcumin may promote iron deﬁciency even under conditions of
sufﬁcient iron intake. Consistent with depleted hepatic iron stores
in our curcumin-supplemented mice, mRNA and protein levels of
the L subunit of the iron storage protein ferritin were reduced in
the liver. In partial agreement with our results, liver ferritin was
decreased in mice after a 12 week 2% curcuminoids (1.5% curcu-
min) dietary supplementation, but not in mice fed 0.5% curcumi-
noids (0.4% curcumin) [31]. Additionally, in a model of iron
depletion (5 mg iron/kg diet), 2% curcumin supplementation for
6 months induced alterations in haematological parameters,
reduced iron stores in the spleen, and reduced ferritin concentra-
tions in the liver. However, contrary to the observations made in
our study, none of these parameters were changed in mice fed iron
at Z12 mg/kg diet, and lower curcumin doses including the dose
we used (0.2% curcumin) had no adverse effects on iron status in
these mice [10]. On the other hand, the mice used in this study
were only 5 weeks old at the beginning of the experiment and
may therefore have had different dietary iron requirements
compared to our mice which were 12 months old.
In our model, middle-aged mice were fed a Western-type diet
(20% fat and 10% sugar) to simulate human dietary habits, where
curcumin supplements are often taken for potential health promot-
ing effects. Supplement users may have multiple disease-risk factors,
including advanced age, obesity, and unbalanced diets rich in fat and
sugars. Interestingly, a high-fat diet has been suggested to promote
iron deﬁciency by reducing duodenal iron absorption and by
inducing inﬂammation [32,33]. Although our mice were supplied
with adequate dietary iron, curcumin supplementation markedly
depleted iron stores in the presence of theWestern-type diet (Fig. 3).
To provide further evidence of the observed iron deﬁciency,
hepcidin mRNA expression was measured in the liver. Hepcidin is
an antimicrobial peptide that is synthesised in the liver and is
involved in the regulation of iron homoeostasis by inhibiting the
iron exporter FPN [24]. Hepcidin is a reliable marker that reﬂects
iron requirements of the body as its expression is induced when
iron stores are high and suppressed when iron stores are low [34].
However, hepcidin expression can also be altered during inﬂam-
mation, erythropoiesis, and hypoxia [35]. In our study, the expres-
sion of hepcidin was signiﬁcantly reduced in the liver of curcumin-
fed mice along with depleted iron stores in the liver and the
spleen. As the expression of inﬂammatory markers did not differ
between control and curcumin-supplemented mice in our study, a
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Fig. 5. Expression of (a) hepcidin (HEPC), (b) ferroportin (FPN), (c) divalent metal transporter (DMT) 1, and (d) transferrin receptor (TfR) 1 mRNA in the liver of control and
curcumin-supplemented C57BL/6J mice. Relative mRNA concentration was assessed using qRT-PCR and related to the average of two housekeeping genes (β-actin and
GAPDH). The mean expression levels of genes in the control group were set to be 1. The mRNA expression of hepcidin was signiﬁcantly lower in curcumin-supplemented
mice, while the expressions of iron transport proteins DMT1 and TfR1 were signiﬁcantly increased. FPN was not signiﬁcantly regulated. Values are expressed as meansþSEM.
nPo0.05, nnPo0.01.
Table 2
Expression of tumour necrosis factor α (TNFα), interleukin 1β (IL1β), and 6 (IL6)
mRNA in the liver and spleen; and of nuclear factor (erythroid-derived 2)-like 2
(NRF2), haem oxygenase 1 (HO1), NAD(P)H quinone oxidoreductase (NQO1), and
γ-glutamyl cysteine synthetase (γ-GCS) heavy chain mRNA in the liver of control
and curcumin supplemented C57BL/6J mice. Relative mRNA concentration was
assessed using qRT-PCR and related to the average of two housekeeping genes (β-
actin and GAPDH) in both tissues. The mean expression levels of genes in the
control group were set to be 1. No signiﬁcant differences between the groups were
observed. Values are expressed as means7SEM.
Control Curcumin
Liver TNFα 1.0070.14 1.1170.07
IL1β 1.0070.12 1.2970.18
IL6 1.0070.11 1.0270.10
NRF2 1.0070.09 1.1270.08
HO1 1.0070.12 1.1770.10
NQO1 1.0070.11 1.0270.10
γ-GCS 1.0070.14 0.8970.09
Spleen TNFα 1.0070.06 1.1670.09
IL1β 1.0070.08 0.9470.13
IL6 1.0070.05 0.8670.08
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possible effect of inﬂammation on hepcidin expression may be
excluded.
FPN is the only known mammalian iron exporter and the main
receptor for hepcidin [36], but its hepatic mRNA levels did not
differ between groups in our study (Fig. 5b). Although transcrip-
tional regulation of FPN in hepatocytes by hepcidin has been
shown [37], hepcidin mainly stimulates the degradation of FPN
protein [24], thereby modulating its activity. Additionally, curcu-
min supplementation induced the expression of the two hepatic
iron importers DMT1 and TfR1 (Fig. 5c and d).
Curcumin has been described as possessing anti-inﬂammatory
properties [25–27] and as an inducer of NRF2 and therefore NRF2-
controlled genes, such as HO1 [28–30]. In our study, however,
curcumin did not signiﬁcantly regulate the pro-inﬂammatory mar-
kers TNFα, IL1β, and IL6 in the liver and the spleen (Table 2).
Likewise, curcumin had no effect on NRF2, and the NRF2-dependent
enzymes HO1, NQO1, and γGCS in the liver (Table 2). These ﬁndings
are in agreement with our observations in the hearts of SAMP8 mice
fed curcumin for 5 months [38,39], but are in contrast to cell culture
[40] and mouse studies [41] that suggest NRF2-induction by curcu-
min. A reason for the absence of NRF2-induction by curcumin in our
mice could be its low oral bioavailability and subsequent low hepatic
concentrations. Total curcumin concentrations in the liver of our
mice (data not shown) were below the limit of detection of our
analytical method [15]. Nevertheless, given the observed effects on
iron status, it seems possible that the relatively high concentrations
of unabsorbed curcumin in the intestinal tract may have exerted local
biological effects. The β-diketone moiety of the curcumin molecule
has been shown to be the active site involved in the chelation of iron,
suggesting the formation of curcumin:iron complex species in the
ratio of 1:1 [6]. The molar ratio of curcumin to iron in the diet used in
our experiments was 1.7–1. Thus, based on the iron-chelating
properties of curcumin [6], the curcumin present in our diet may
have been sufﬁcient to chelate most of the iron in the diet and might
thereby have induced the iron deﬁciency observed in our mice.
It should also be kept in mind that anti-coagulant activities of
curcumin [11,12], which may lead to gastrointestinal bleeding, could
not be excluded in our study and might be an alternative mechanism
that may have contributed to the observed iron deﬁciency in
our mice.
We further observed a 40% increase in spleen mass in the
curcumin-supplemented mice, which was not associated with
increased inﬂammation in the spleen, since the expression of pro-
inﬂammatory cytokines TNFα, IL1β, and IL6 was not induced
(Table 2). The spleen is one of the most sensitive organs with regard
to nutritional iron deﬁciency [42]. It has previously been shown that
iron deﬁciency can increase spleen mass in mice [43,44]. A possible
explanation for iron deﬁciency-induced increase in spleen mass
could be the sequestering of an increased number of abnormal and
damaged erythrocytes, resulting from iron deﬁciency, by the reticu-
loendothelial system in the spleen [45]. In our previous studies,
however, we did not observe spleen enlargement when 0.05%
curcumin was fed for 5 months as part of a Western-type diet to
2 month old SAMP8 mice [38,39,46] or at higher concentrations of
0.4% in a standard diet for 4 weeks to rats [47]. On the other hand,
mice infected with Plasmodium berghei developed splenomegaly,
which could be reversed by treatment with a single injection of
arteether combined with oral doses of 5 mg curcumin per day for
3 days [48]. Therefore, it remains uncertain if the enlargement of the
spleen observed in this experiment was caused by the curcumin
induced iron deﬁciency. It is further unclear whether an unknown
interaction between curcumin and environmental factors or the
Western-type diet, which was used, could have contributed to this
observation. Further experiments are required to conﬁrm or refute
the curcumin-induced enlargement of the spleen observed in
our mice.
In conclusion, the presented data suggest a potentially adverse
biological activity of high-dose curcumin supplementation that
might lead to impaired iron absorption and status. It may hence be
worthwhile monitoring the iron status in subjects participating in
clinical trials during which high doses of native curcumin are
administered. Since complexation of iron might be the underlying
mechanism, encapsulation of curcumin (e.g., incorporation into
micelles or liposomes) may help to reduce its direct interaction
with transition metals and thereby their chelation. Micelles and
liposomes have been used as vehicles to improve the bioavail-
ability of curcumin [49,50,51] and provide the additional advan-
tage that lower oral doses can be administered, which would lead
to a smaller number of potential curcumin:iron complexes and
thus a reduced potential for adverse effects on iron status.
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